文献速递膀胱癌与上尿路尿路上皮癌

T1期膀胱癌差异性肿瘤亚型的鉴定

Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
PubMed 文献 · Eur Urol · 2020-07-17

该研究对接受重复经尿道电切及卡介苗诱导和维持治疗的T1期膀胱癌进行转录组测序和无监督聚类,识别出五种共识亚型;T1-LumGU与原位癌相关,T1-Myc和T1-Early复发最多且无复发生存显著更差;研究开发了单患者分类器并在第二队列中验证了亚型生物学特征。

要点

  • T1-LumGU亚型富集原位癌且E2F1、EZH2高表达。
  • T1-TLum亚型管腔乳头评分和FGFR3表达最高,无复发事件。
  • T1-Myc和T1-Early亚型复发最多,无复发生存显著更差。

核心结论

  • T1期膀胱癌存在五种表达亚型,生物学异质且对卡介苗治疗反应不同,T1-Myc和T1-Early亚型复发风险更高。

研究设计与样本

  • 对接受重复经尿道电切及卡介苗诱导和维持治疗的T1期肿瘤进行转录组测序和无监督聚类,开发单患者分类器并在第二T1肿瘤队列中验证亚型生物学。

主要发现

  • T1-LumGU亚型中6/13(46%)的原位癌属于该亚型,且E2F1和EZH2高表达并富集E2F靶点和G2M检查点标志。
  • T1-Inflam亚型呈炎症状态并有免疫细胞浸润;T1-TLum亚型管腔乳头评分中位数和FGFR3表达最高,无复发事件且拷贝数增益最少。
  • T1-Myc和T1-Early亚型复发最多(30例中24个月内14例复发),MYC表达中位数最高,合并后无复发生存显著差于其他三型。
  • T1-Early亚型在卡介苗开始后前6个月内出现5例(38%)复发,并抑制IFN-α、IFN-γ标志和炎症。

临床怎么用

  • 基于表达亚型可识别复发风险更高的T1期膀胱癌患者,未来或可据此个体化治疗,但当前仍需前瞻性验证。

局限性

  • 需要未来研究验证所提出的T1亚型,并确定能否为每个亚型个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle-invasive bladder cancers (NMIBCs). Most T1 cancers are treated with bacillus Calmette-Guérin (BCG), but many will progress or recur, and some T1 patients will die from bladder cancer. Particularly aggressive tumors could be treated with early cystectomy. To better understand the molecular heterogeneity of T1 cancers, we performed transcriptome profiling and unsupervised clustering, and identified five consensus subtypes of T1 tumors treated with repeat transurethral resection (reTUR) and induction and maintenance BCG. The T1-LumGU subtype was associated with carcinoma in situ (CIS; six/13, 46% of all CIS), had high E2F1 and EZH2 expression, and was enriched in E2F target and G2M checkpoint hallmarks. The T1-Inflam subtype was inflamed and infiltrated with immune cells. While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median luminal papillary score and FGFR3 expression, no recurrence events, and the fewest copy number gains. T1-Myc and T1-Early subtypes had the most recurrences (14/30 within 24 mo), the highest median MYC expression, and, when combined, had significantly worse recurrence-free survival than the other three subtypes. T1-Early had five (38%) recurrences within the first 6 mo of BCG, and repressed IFN-α and IFN-γ hallmarks and inflammation. We developed a single-patient T1 classifier and validated our subtype biology in a second cohort of T1 tumors. Future research will be necessary to validate the proposed T1 subtypes and to determine if therapies can be individualized for each subtype. PATIENT SUMMARY: We identified and characterized expression subtypes of high-grade stage T1 bladder cancer that are biologically heterogeneous and have variable responses to bacillus Calmette-Guérin treatment. We validated the subtypes and describe a single-patient classifier.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Robertson AG, Groeneveld CS, Jordan B, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. 2020. PMID: 32684305. doi:10.1016/j.eururo.2020.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。